Merida Biosciences
Recent Finacing
Series A
Recent Raise
$121M
Merida Biosciences develops Fc-engineered therapeutics that selectively bind and neutralize pathogenic antibodies and target autoreactive B cells, pursuing programs in Graves’ disease, allergy, and primary membranous nephropathy.
Highlights
Focus Areas
Biotechnology
Life Science
Therapeutics
Recent Investors
Financials
$121M
Total Raised
1
Funding round
5
Investors